Showing 1351-1360 of 21414 results for "".
- Transcriptomic Study Identifies IL-1β Axis in Hidradenitis Suppurativahttps://reachmd.com/news/transcriptomic-study-identifies-il-1b-axis-in-hidradenitis-suppurativa/2486448/Comprehensive transcriptomic profiling of hidradenitis suppurativa (HS) highlights a dominant macrophage-derived IL-1β/NLRP3 inflammasome axis, p
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://reachmd.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- Gut commensals Use Injection Systems to Deliver Eeffectors That Modulate Host Immunityhttps://reachmd.com/news/gut-commensals-use-injection-systems-to-deliver-effectors-that-modulate-host-immunity/2486403/Investigators described evidence that many commensal Pseudomonadota from healthy human gut microbiomes can deploy syringe-like secretion apparatus and deliver
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://reachmd.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://reachmd.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://reachmd.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://reachmd.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.
- Survey Highlights Misinformation’s Growing Impact on Public Trust and Health Perceptionhttps://reachmd.com/news/survey-highlights-misinformations-growing-impact-on-public-trust-and-health-perception/2486387/A new national survey from The Harris Poll paints a complex and increasingly consequential picture of how Americans engage with health and science inf
- ILDS, WHO Launch Global Dermatology Training Hub to Address Care Gapshttps://reachmd.com/news/ilds-who-launch-global-dermatology-training-hub-to-address-care-gaps/2486380/The International League of Dermatological Societies (ILDS), in collaboration with the World Health Organization (WHO), has launched the ILDS Dermatology Training Hub, a free online platform aimed at expanding access to dermatology education worldwide. The initiati
- SystImmune to Present iza‑bren (BL‑B01D1) Phase II ES‑SCLC Data at ELCC 2026https://reachmd.com/news/systimmune-to-present-izabren-blb01d1-phase-ii-essclc-data-at-elcc-2026/2486360/SystImmune announced that safety and efficacy results for iz